AD Pipeline Watch: First Patient Enrolled in Phase 2 Study of Evommune’s IL-18 Blocker March 17, 2025
AD Pipeline Watch: Amgen, Kyowa Kirin’s Anti-OX40 Candidate Meets Endpoints in AD Trial March 10, 2025
Unpacking the Latest Results From The ADORING 3 Study of Tapinarof in AD With Linda Stein Gold, MD March 8, 2025
Taking a Deep Dive Into Three-year Data on Lebrikizumab in AD With Raj Chovatiya, MD, PhD March 7, 2025
